UBI Asia
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
UBI Asia - overview
Established
1998
Location
Taipei, -, Taiwan - China
Primary Industry
Biotechnology
About
Founded in 1998 and based in Taipei, China, UBI Asia is a biotech company that focuses on the development of human vaccines and animal vaccines. In January 1998, the firm raised TWD 700 million in strategic investment from new investor National Development Fund of the Executive Yuan. In 2003, the company developed a synthetic peptide foot-and-mouth disease vaccine for pigs. In 2015, its UBITh® boar castration vaccine obtained drug licenses in Brazil, Mexico and Taiwan.
Changyi Wang, the company's founder, chairman and CEO, formerly served as director of the molecular immunology laboratory and research program leader at Memorial Sloan Kettering Cancer Research Center. The company's main products include human vaccines and animal vaccines. Human vaccines include UB-612 COVID vaccine and anti-IL-6 human vaccine. Animal vaccines include pig immune castration vaccine and type O foot-and-mouth disease synthetic peptide vaccine.
Current Investors
National Development Fund of the Executive Yuan
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.ubiasia.com
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.